"So the two main reasons we need new therapies are they need to be more effective for these patients with resistance and to overcome the fact that we're not curing everybody. Two, we need drugs that are less toxic. That enters in the era of targeted therapy. To design based on a molecular understanding of the biology of the disease so that we can counteract those mechanisms and reverse those mechanisms hopefully systemically such that there should be improved efficacy with less toxicity."